OSI Pharmaceuticals, Genentech and Roche Announce Interim Clinical Data From Phase II Cancer Studies of the Anti-EGFR Therapy Tarceva(TM) (OSI-774)
(PR Newswire)...single agent study required failure of at least one round of platinum-based chemotherapy and to have tumors that are EGFR-positive.......Objective clinical responses were evaluated at 8 and 12 weeks and classified as either complete responses, partial responses (>50 percent reduction in tumor size), stable disease, or progressive disease (>......Further studies are in discussion with the U.S. National Cancer Institute`s Cancer Therapy Evaluation Program (CTEP) to collaborate with OSI to conduct clinical trials in multiple tumor types including epithelial malignancies of the gastrointestinal and genitourinary tracts, gynecological malignancies and brain tumors....- May 12 7:45 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010512/nysa001.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines